Hypothesis

Resveratrol’s reported SIRT1 activation may be an artifact of its antioxidant activity; a true sirtuin‑specific signal can be isolated by measuring changes in the epitranscriptomic mark ac4C on GABABR1 mRNA via the SIRT1‑NAT10 axis.

Rationale

• SIRT1 deacetylates NAT10, decreasing ac4C modification on GABABR1 mRNA [4].
• ac4C levels are not directly influenced by cellular ROS or glutathione, offering a kinetic readout decoupled from redox noise [3].
• Resveratrol’s primary validated actions are AMPK activation and NF‑κB inhibition [2], which do not directly alter NAT10 activity.

Thus, if resveratrol truly activates SIRT1, we should observe a reproducible decrease in GABABR1‑ac4C independent of changes in GSH/GSSG ratio or MDA levels.

Experimental Design

1. Cell model – Human primary fibroblasts or iPSC‑derived hepatocytes treated with resveratrol (0‑50 µM) and matched NAC (antioxidant) controls.
2. Treatments – (a) Vehicle, (b) Resveratrol, (c) Resveratrol + SIRT1 inhibitor (EX‑527), (d) Resveratrol + AMPK inhibitor (Compound C), (e) NAC alone.
3. Readouts –
   • ac4C‑IP followed by qPCR for GABABR1 transcripts (epitranscriptomic SIRT1 activity).
   • Direct SIRT1 deacetylation assay (p53‑Ac382 Western).
   • Redox markers: GSH/GSSG, MDA, SOD activity.
   • Phospho‑AMPK and IκBα degradation for pathway confirmation.
4. Kinetic sampling – 0, 0.5, 1, 2, 4, 8, 24 h to capture early epitranscriptomic changes before significant metabolite accumulation.

Expected Outcomes

• If hypothesis true: Resveratrol reduces GABABR1‑ac4C with similar kinetics to p53 deacetylation; this effect is blocked by EX‑527 but not by AMPK or NAC; redox markers remain unchanged.
• If hypothesis false: No change in ac4C, or changes mirror those seen with NAC (indicating redox‑driven effect), or are abolished by AMPK inhibition.

Falsifiability

A single experiment showing that resveratrol‑induced ac4C reduction is prevented by NAC (antioxidant) but not by EX‑527 would falsify the claim that the mark reports SIRT1‑specific activity.

Broader Impact

Validating this readout would enable polyphenol screening free from antioxidant confounders, clarify resveratrol’s mechanism, and guide nano‑delivery trials that target the SIRT1‑NAT10‑GABABR1 axis in human aging models.

Key References

[1] [2] [3] [4] [5] [6]